Advertisement

Tumor Biology

, Volume 35, Issue 6, pp 5481–5486 | Cite as

Clinical implication of TMPRSS4 expression in human gallbladder cancer

  • Xiao-Yang Wu
  • Li Zhang
  • Ke-Ming Zhang
  • Ming-Hua Zhang
  • Ting-Yan Ruan
  • Chao-Ying Liu
  • Jun-Ying Xu
Research Article

Abstract

Altered expression of transmembrane protease/serine 4 (TMPRSS4) is observed in various types of human cancers. However, the clinical significance of TMPRSS4 expression in gallbladder cancer (GBC) remains largely unknown. The present study aims to explore the clinicopathological significance and prognostic value of TMPRSS4 in GBC. The levels of TMPRSS4 mRNA and protein in GBC tissues and adjacent noncancerous tissues were evaluated by quantitative reverse-transcriptase polymerase chain reaction and immunohistochemistry. To investigate the correlations between TMPRSS4 and the clinicopathological features of GBC, the expression of TMPRSS4 in 97 patients with GBC were detected by immunohistochemistry. The correlation of TMPRSS4 expression with patients’ survival rate was assessed by Kaplan–Meier and Cox regression. Our results showed that the expression levels of TMPRSS4 mRNA and protein in GBC tissues were both significantly higher than those in adjacent noncancerous tissues. Immunohistochemical staining revealed that high TMPRSS4 expression was closely correlated with tumor size (P = 0.032), histological grade (P = 0.002), pathologic T stage (P = 0.005), clinical stage (P = 0.013), and lymph node metastasis (P = 0.003). Moreover, the results of Kaplan–Meier analysis indicated that a high expression level of TMPRSS4 resulted in a significantly poor prognosis of GBC patients. Multivariate analysis showed that the status of TMPRSS4 expression was an independent prognostic factor for GBC patients. Our results showed that TMPRSS4 plays a key role in GBC and therefore may provide an opportunity for developing a novel therapeutic target as well as a prognostic marker in GBC.

Keywords

TMPRSS4 Immunohistochemistry qRT-PCR Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;19:252–64. doi: 10.1016/j.amjsurg.2007.11.011.CrossRefGoogle Scholar
  3. 3.
    Balachandran P, Agarwal S, Krishnani N, Pandey CM, Kumar A, Sikora SS, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006;10:848–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim WS, Choi DW, You DD, Ho CY, Heo JS, Choi SH. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14:679–87. doi: 10.1007/s11605-009-1140-z.CrossRefPubMedGoogle Scholar
  5. 5.
    Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 2001;276:857–60. doi: 10.1074/jbc.R000020200.CrossRefPubMedGoogle Scholar
  6. 6.
    Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003;22:237–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Szabo R, Wu Q, Dickson RB, Netzel-Arnett S, Antalis TM, Bugge TH. Type II transmembrane serine proteases. Thromb Haemost. 2003;90:185–93.PubMedGoogle Scholar
  8. 8.
    Webb SL, Sanders AJ, Mason MD, Jiang WG. Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci (Landmark Ed). 2011;16:539–52.CrossRefGoogle Scholar
  9. 9.
    Wallrapp C, Hähnel S, Müller-Pillasch F, Burghardt B, Iwamura T, Ruthenbürger M, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 2000;60:2602–6.PubMedGoogle Scholar
  10. 10.
    Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodríguez MJ, et al. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Br J Cancer. 2011;105:1608–14. doi: 10.1038/bjc.2011.432.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Nguyen TH, Weber W, Havari E, Connors T, Bagley RG, McLaren R, et al. Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia. Int J Oncol. 2012;41:829–38. doi: 10.3892/ijo.2012.1513.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587–97. doi: 10.1158/0008-5472.CAN-04-3078.CrossRefPubMedGoogle Scholar
  13. 13.
    Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg. 2005;242:353–61. doi: 10.1097/01.sla.0000179623.87329.6b. discussion 361-3.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer. 2006;106:2592–7. doi: 10.1002/cncr.21922.CrossRefPubMedGoogle Scholar
  15. 15.
    Cheng D, Kong H, Li Y. TMPRSS4 as a poor prognostic factor for triple-negative breast cancer. Int J Mol Sci. 2013;14:14659–68. doi: 10.3390/ijms140714659.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Liang B, Wu M, Bu Y, Zhao A, Xie F. Prognostic value of TMPRSS4 expression in patients with breast cancer. Med Oncol. 2013;30:497. doi: 10.1007/s12032-013-0497-8.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong CS, et al. TMPRSS4 induces invasion and epithelial–mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis. 2010;31:597–606. doi: 10.1093/carcin/bgq024.CrossRefPubMedGoogle Scholar
  18. 18.
    Jung H, Lee KP, Park SJ, Park JH, Jang YS, Choi SY, et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial–mesenchymal transition. Oncogene. 2008;27:2635–47. doi: 10.1038/sj.onc.1210914.CrossRefPubMedGoogle Scholar
  19. 19.
    Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009;69:1828–35. doi: 10.1158/0008-5472.CAN-08-3728.CrossRefPubMedGoogle Scholar
  20. 20.
    Jia JB, Wang WQ, Sun HC, Liu L, Zhu XD, Kong LQ, et al. A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. Invest New Drugs. 2011;29:861–72. doi: 10.1007/s10637-010-9435-1.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee HK, Cho MS, Kim TH. Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Oncol. 2012;10:224. doi: 10.1186/1477-7819-10-224.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xiao-Yang Wu
    • 1
    • 2
  • Li Zhang
    • 3
  • Ke-Ming Zhang
    • 4
  • Ming-Hua Zhang
    • 5
  • Ting-Yan Ruan
    • 6
  • Chao-Ying Liu
    • 6
  • Jun-Ying Xu
    • 6
  1. 1.Department of Cardiovascular SurgeryThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of General SurgeryKunshan First People’s Hospital Affiliated to Jiangsu UniversityKunshanChina
  3. 3.Department of GastroenterologyKunshan First People’s Hospital Affiliated to Jiangsu UniversityKunshanChina
  4. 4.Department of Minimally Invasive SurgeryWuxi People’s Hospital Affiliated to Nanjing Medical UniversityWuxiChina
  5. 5.Department of Hepatobiliary SurgeryKunshan First People’s Hospital Affiliated to Jiangsu UniversityKunshanChina
  6. 6.Department of Medical OncologyWuxi People’s Hospital Affiliated to Nanjing Medical UniversityWuxiChina

Personalised recommendations